Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Chaudhary, Surendra Pal
199  Ergebnisse:
Personensuche X
?
1

Phase I Trial of First-line Bintrafusp Alfa in Patients wit..:

Oaknin, Ana ; Ghamande, Sharad A. ; Kasamatsu, Yuka...
Clinical Cancer Research.  30 (2024)  5 - p. 975-983 , 2024
Link: https://doi.org/10.1158/..
 
?
2

A phase 2 clinical trial of the heat shock protein 90 (HSP ..:

Goyal, Lipika ; Chaudhary, Surendra Pal ; Kwak, Eunice L....
Investigational New Drugs.  38 (2020)  5 - p. 1533-1539 , 2020
Link: https://doi.org/10.1007/..
 
?
3

RevisitingMET: Clinical Characteristics and Treatment Outco..:

Chaudhary, Surendra Pal ; Kwak, Eunice L. ; Hwang, Katie L....
The Oncologist.  25 (2020)  11 - p. e1691-e1700 , 2020
Link: https://doi.org/10.1634/..
 
?
4

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (H..:

Pal Chaudhary, Surendra ; Reyes, Stephanie ; Chase, Matthew L...
The Oncologist.  28 (2023)  4 - p. 341-350 , 2023
Link: https://doi.org/10.1093/..
 
?
5

Modified gemcitabine and oxaliplatin or gemcitabine + cispl..:

Sharma, Atul ; Kalyan Mohanti, Bidhu ; Pal Chaudhary, Surendra...
European Journal of Cancer.  123 (2019)  - p. 162-170 , 2019
Link: https://doi.org/10.1016/..
 
?
6

Revisiting MET: Clinical Characteristics and Treatment Outc..:

Chaudhary, Surendra Pal ; Kwak, Eunice L ; Hwang, Katie L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648344/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
7

Supplementary Table S3 from Phase I Trial of First-line Bin..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324491.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
8

Supplementary Table S3 from Phase I Trial of First-line Bin..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324491.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
9

Supplementary Table S4 from Phase I Trial of First-line Bin..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324488.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
10

Supplementary Figure S1 from Phase I Trial of First-line Bi..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324509.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
11

Supplementary Figure S2 from Phase I Trial of First-line Bi..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324506.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
12

Supplementary Table S1 from Phase I Trial of First-line Bin..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324497.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
13

Supplementary Table S2 from Phase I Trial of First-line Bin..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324494.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
14

Supplementary Figure S3 from Phase I Trial of First-line Bi..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324503.v1.  , 2024
Link: https://doi.org/10.1158/..
 
?
15

Supplementary Figure S1 from Phase I Trial of First-line Bi..:

Ana Oaknin ; Sharad A. Ghamande ; Yuka Kasamatsu...
doi:10.1158/1078-0432.25324509.v1.  , 2024
Link: https://doi.org/10.1158/..
 
1-15